Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis

BACKGROUND: Disease-modifying treatments are in development for Huntington's disease; crucial to their success is to identify a timepoint in a patient's life when there is a measurable biomarker of early neurodegeneration while clinical function is still intact. We aimed to identify this t...

Descripción completa

Detalles Bibliográficos
Autores principales: Scahill, Rachael I, Zeun, Paul, Osborne-Crowley, Katherine, Johnson, Eileanoir B, Gregory, Sarah, Parker, Christopher, Lowe, Jessica, Nair, Akshay, O'Callaghan, Claire, Langley, Christelle, Papoutsi, Marina, McColgan, Peter, Estevez-Fraga, Carlos, Fayer, Kate, Wellington, Henny, Rodrigues, Filipe B, Byrne, Lauren M, Heselgrave, Amanda, Hyare, Harpreet, Sampaio, Cristina, Zetterberg, Henrik, Zhang, Hui, Wild, Edward J, Rees, Geraint, Robbins, Trevor W, Sahakian, Barbara J, Langbehn, Douglas, Tabrizi, Sarah J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254065/
https://www.ncbi.nlm.nih.gov/pubmed/32470422
http://dx.doi.org/10.1016/S1474-4422(20)30143-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254065/
https://www.ncbi.nlm.nih.gov/pubmed/32470422
http://dx.doi.org/10.1016/S1474-4422(20)30143-5

Ejemplares similares